Dendreon Gets $28M Revenue in Q1
Seattle-based Dendreon (NASDAQ: DNDN), the maker of an immune-boosting therapy for prostate cancer, said today it generated $28.1 million in revenue in the quarter that ended March 30. Dendreon also said it had $15 million in sales in the month of April, which reflects its increased manufacturing capacity for making sipuleucel-T (Provenge) at a factory in New Jersey. The company reiterated that it plans to generate $350 million to $400 million in sales this year. The company had a net loss of $112 million in the first quarter, and ended March with $779 million of cash and investments in the bank.